logo

IMRN

Immuron
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
Ample Liquidity
High Gross Profit Margin

Key Stats

0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000

About IMRN

Immuron Limited

An Australian developer of immunomodulator polyclonal antibodies that treats liver disease and infectious diseases

Pharmaceutical
Invalid Date
06/09/2017
NASDAQ Stock Exchange
7
06-30
Depository Receipts (Ordinary Shares)
Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia
Focus on providing oral immunotherapy to humans using dairy-derived antibody products
Immuron Limited was established in 1994 under the laws of Australia. The Company is a commercial and clinical-stage biopharmaceutical company with a patented technology platform focused on the development and commercialization of a new class of specifically targeted polyclonal antibodies that the Company believes address serious unmet medical needs.

Company Financials

EPS

IMRN has released its 2022 Q4 earnings. EPS was reported at -0.01, versus the expected 0, missing expectations. The chart below visualizes how IMRN has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime